Immuron Ltd

General Information

(Note: Our ordinary shares are listed on the Australian Securities Exchange under the symbol “IMC” since 2012.)

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. Our lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune mediated diseases including fatty-liver diseases.

Employees: 8
Founded: 1994
Contact Information
Address Suite 1, 1233 High Street, Armadale, Victoria, Australia 3143
Phone Number +61 (0)3 9824 5254.
Web Address
View Prospectus: Immuron Ltd
Financial Information
Market Cap
Revenues $0.7 mil (last 12 months)
Net Income $-5.1 mil (last 12 months)
IPO Profile
Symbol IMROY
Exchange NASDAQ
Shares (millions): 0.0
Price range $8.80 - $8.80
Est. $ Volume $17.3 mil
Manager / Joint Managers Joseph Gunnar & Co.
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change